ClinicalTrials.gg
CompletedNCT00861601Updated May 12, 2015Results posted

Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease

A Phase 2 interventional study of eltrombopag 12.5 milligrams (mg) tablet and eltrombopag 25 mg tablet in Liver Diseases, sponsored by GlaxoSmithKline. Completed at 10 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-05-12.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Liver Diseases with a site in Japan — 4 open to participants now, 4 under way, 1 of them phase 3. Liver Diseases · Japan.

Enrollment
10th of 12
38 · median 77
Started
2009
the only one that year
Phase 2
4 of 14
1 open now
Registered
4th of 14
by date
Lead sponsor
1 of 14
GlaxoSmithKline

Among the 14 studies in Liver Diseases with a site in Japan, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2009, is one of 4 in phase 2, and was the 4th registered.

Liver Diseases

825 studies on the registry are indexed under Liver Diseases; 153 are open to participants now.

Browse Liver Diseases studies →

Open to participants now

4 of the 14 studies in Liver Diseases with a site in Japan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 103 Liver Diseases studies recruiting now, 51 (50%) set no upper age limit and 30 (29%) stop at 75 or younger; 19 take children under 18; 19 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Liver Diseases with a site in Japan, or all of them as a file.
02

Study summary

This is an open label, multi-centre, dose ranging study to assess efficacy, safety and pharmacokinetics of eltrombopag in thrombocytopenic subjects with chronic liver disease.

03

Conditions studied

  • Liver Diseases

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject who agree to comply with protocol requirements and instructions and who provide signed and dated written .
  • Male and female subjects, ≥20 years of age (at the time of informed consent) with chronic liver disease.
  • score \<=9.
  • A baseline count \<50,000/mcL.
  • A baseline serum sodium level >130 mEq/L.
  • concentration >8 g/dL, stable for at least 4 weeks.
  • A female is eligible to enter and participate in the study if she is of:

Non- (i.e., physiologically incapable of becoming pregnant) including any female who:

  • Has had a hysterectomy
  • Has had a bilateral oophorectomy (ovariectomy)
  • Has had a bilateral tubal ligation
  • Is (demonstrate total cessation of menses for longer than one year)

Childbearing potential, has a negative urine and/or serum pregnancy test at screening, and within the 24 hour period prior to the first dose of product and uses one of the following acceptable methods of :

  • Complete abstinence from intercourse.
  • Any intrauterine device (IUD) with a documented failure rate of less than 1% per year.
  • Double-barrier contraception (condom with spermicidal jelly, or diaphragm with spermicide).
  • Male partner who is sterile (diagnosed by a qualified medical professional) prior to the female subject's study entry and is the sole sexual partner for that female.
  • Oral contraceptive (combined).
  • Subject has no physical limitation to ingest and retain oral medication.

Exclusion criteria

Exclusion Criteria:

  • Subjects with known or suspected , intolerance or allergy to any of the ingredients in eltrombopag tablets.
  • Evidence of portal vein thrombosis on abdominal imaging (ultrasound with Doppler or appropriate magnetic resonance imaging/computed tomography (MRI/CT) imaging techniques) within 3 months before the start of the study.
  • History of arterial or venous thrombosis (including Budd-Chiari Syndrome),

AND ≥ two of the following risk factors:

  • hereditary thrombophilic disorders (e.g. antithrombinIII (ATIII) deficiency, etc.)
  • hormone replacement therapy
  • systemic therapy (containing oestrogen)
  • smoking
  • diabetes
  • hypercholesterolemia
  • medication for hypertension or cancer
  • (HIV) infection.
  • History of drug/alcohol abuse or dependence within 1 year prior to screening.
  • Any disease condition associated with current active World Health Organization (WHO) Grade 3 or 4 bleeding.
  • Active infection requiring systemic antibiotic therapy.
  • Pregnant, nursing mothers, women who may be pregnant, or women who plan to become pregnant during the time of study participation.
  • Treatment with transfusion within 2 weeks prior to Day 1.
  • Treatment with interferon within 4 weeks prior to Day 1.
  • Treatment with an drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication.
  • History of platelet agglutination abnormality.
  • History of porphyria.
  • Subjects who are deemed unsuitable for the study by the investigator (or subinvestigator).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    low dose

    eltrombopag 12.5 mg/day

    Drug: eltrombopag 12.5 milligrams (mg) tablet

  • Experimental
    middle dose

    eltrombopag 25 mg/day

    Drug: eltrombopag 25 mg tablet

  • Experimental
    high dose

    eltrombopag 37.5 mg/day

    Drug: eltrombopag 12.5 milligrams (mg) tablet · Drug: eltrombopag 25 mg tablet

Interventions

  • Drugeltrombopag 12.5 milligrams (mg) tablet

    eltrombopag 12.5 mg tablet once a day

  • eltrombopag 25 mg tablet once a day

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Platelet Counts on Day 15

    Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.

    Time frame: Baseline, Day 15

Secondary outcomes

  1. Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline Platelet Counts as Covariate)

    Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.

    Time frame: Baseline, Day 15

  2. Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline of Platelet Counts and Child-Pugh Class as Covariates)

    Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts and Child-Pugh class as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.

    Time frame: Baseline, Day 15

  3. Percent Change From Baseline in Platelet Counts on Day 15

    Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.

    Time frame: Baseline, Day 15

  4. Platelet Counts by Treatment Visit

    Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.

    Time frame: Day 1 (Baseline), Day 8, Day 15, and Final Assessment Point (Day 15 or Day 22)

  5. Platelet Counts by Post-Treatment Visit

    Platelet counts were measured by blood draw.

    Time frame: 4 days post-treatment, 8 days post-treatment, and 15 days post-treatment

  6. Platelet Counts at Day 22

    Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.

    Time frame: Day 22

  7. Change From Baseline in Platelet Counts by Treatment Visit

    Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22. Change from Baseline was calculated as the value at each visit minus the Baseline value.

    Time frame: Baseline, Day 8, Day 15, and Final Assessment Point (Day 15 or Day 22)

  8. Change From Baseline in Platelet Counts by Post-Treatment Visit

    Platelet counts were measured by blood draw. Change from Baseline was calculated as the value at each visit minus the Baseline value.

    Time frame: 4 days post-treatment, 8 days post-treatment, and 15 days post-treatment

  9. Percentage of Responders on Day 15

    A responder was defined as a participant with a platelet count within the target range (\>=80 x 10\^9/Liter) on Day 15.

    Time frame: Day 15

  10. Percentage of Responders on Day 22

    A responder was defined as a participant with a platelet count within the target range (\>=80 x 10\^9/Liter) on Day 22 after receiving eltrombopag for an additional week from Day 15, on which his or her platelet count was \<80 x 10\^9/Liter.

    Time frame: Day 22

  11. Change From Baseline in Platelet Counts on Day 15 by Child-Pugh Class

    Change from Baseline was calculated as the Day 15 value minus the Baseline value. The Child-Pugh (CP) score (ranging from 5 to 15, with 5 being mild and 15 being severe), calculated based on total bilirubin, serum albumin, international normalized ratio, ascites, and hepatic encephalopathy, is used to assess the severity of liver disease. A CP score of 5 or 6 is classified as Class A (mild), a score of 7-9 is classified as Class B (moderate), and a score \>=10 is classified as Class C (severe). Participants with a CP score \<10 were enrolled in the study.

    Time frame: Baseline, Day 15

  12. Change From Baseline in Platelet Counts on Day 15 by Sex

    Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of females and males in each treatment group are illustrated by the "n's" in the category titles.

    Time frame: Baseline, Day 15

  13. Change From Baseline in Platelet Counts on Day 15 by Age

    Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of participants in each age category are illustrated by the "n's" in the category titles.

    Time frame: Baseline, Day 15

  14. Log-transformed Cmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg

    Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Cmax=maximum drug concentration.

    Time frame: Day 14, Day 15

  15. Log-transformed Tmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg

    Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Tmax=maximum drug concentration time.

    Time frame: Day 14, Day 15

  16. Log-transformed AUC(0-t) and AUC(0-24) on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg

    Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. AUC(0-t)=area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration, and AUC(0-24)=area under the concentration-time curve from 0 (pre-dose) to 24 hours.

    Time frame: Day 14, Day 15

07

Results

Posted Sep 23, 2010

Participant flow

Participant flow — Overall Study
MilestoneEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
Started121412
Completed121412
Not completed000

Outcome measures

PrimaryChange From Baseline in Platelet Counts on Day 15

Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.

Time frame:
Baseline, Day 15
Reported as:
Mean · 10^9/Liter
Change From Baseline in Platelet Counts on Day 15
10^9/LiterEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
Change From Baseline in Platelet Counts on Day 1524.8 (8.2 to 41.4)54.0 (28.2 to 79.8)60.0 (29.3 to 90.7)
SecondaryAnalysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline Platelet Counts as Covariate)

Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.

Time frame:
Baseline, Day 15
Reported as:
Mean · 10^9/Liter
Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline Platelet Counts as Covariate)
10^9/LiterEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline Platelet Counts as Covariate)24.8 (8.2 to 41.4)54.0 (28.2 to 79.8)60.0 (29.3 to 90.7)
Statistical analysis
  • Eltrombopag 12.5 mg vs Eltrombopag 25 mg vs Eltrombopag 37.5 mg · ANCOVA · p = 0.0104 (Linearity. This analysis is based on each participants' change in platelet count.)No adjustment for multiplicity was made because this analysis was exploratory.
  • Eltrombopag 12.5 mg vs Eltrombopag 25 mg vs Eltrombopag 37.5 mg · ANCOVA · p = 0.0057 (Saturation at the medium dose. This analysis is based on each participants' change in platelet count.)No adjustment for multiplicity was made because this analysis was exploratory.
  • Eltrombopag 12.5 mg vs Eltrombopag 25 mg vs Eltrombopag 37.5 mg · ANCOVA · p = 0.0808 (Onset of response at the higher dose. This analysis is based on each participants' change in platelet count.)No adjustment for multiplicity was made because this analysis was exploratory.
SecondaryAnalysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline of Platelet Counts and Child-Pugh Class as Covariates)

Exploratory analysis was conducted to see a dose response/trend when a dose goes high with the changes from baseline in platelet counts (12.5 mg, 25 mg, and 37.5 mg) on Day 15 of each subject. The data were analyzed with baseline of platelet counts and Child-Pugh class as covariate for the following dose response pattern using contrast: (1) linearity, (2) saturation at the medium dose, (3) onset of response at the high dose.

Time frame:
Baseline, Day 15
Reported as:
Mean · 10^9/Liter
Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline of Platelet Counts and Child-Pugh Class as Covariates)
10^9/LiterEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
Analysis of Covariance for Three Patterns of Dose Response Using the Change From Baseline in Platelet Counts (Baseline of Platelet Counts and Child-Pugh Class as Covariates)24.8 (8.2 to 41.4)54.0 (28.2 to 79.8)60.0 (29.3 to 90.7)
Statistical analysis
  • Eltrombopag 12.5 mg vs Eltrombopag 25 mg vs Eltrombopag 37.5 mg · ANCOVA · p = 0.0116 (Linearity. This analysis is based on each participants' change in platelet count.)No adjustment for multiplicity was made because this analysis was exploratory.
  • Eltrombopag 12.5 mg vs Eltrombopag 25 mg vs Eltrombopag 37.5 mg · ANCOVA · p = 0.0066 (Saturation at the medium dose. This analysis is based on each participants' change in platelet count.)No adjustment for multiplicity was made because this analysis was exploratory.
  • Eltrombopag 12.5 mg vs Eltrombopag 25 mg vs Eltrombopag 37.5 mg · ANCOVA · p = 0.0846 (Onset of response at the higher dose. This analysis is based on each participants' change in platelet count.)No adjustment for multiplicity was made because this analysis was exploratory.
SecondaryPercent Change From Baseline in Platelet Counts on Day 15

Platelet counts were measured by blood draw. Change from Baseline was calculated as the Day 15 value minus the Baseline value.

Time frame:
Baseline, Day 15
Reported as:
Mean · Percent change
Percent Change From Baseline in Platelet Counts on Day 15
Percent changeEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
Percent Change From Baseline in Platelet Counts on Day 1557.86 (18.77 to 96.94)134.57 (81.36 to 187.78)158.45 (92.32 to 224.59)
SecondaryPlatelet Counts by Treatment Visit

Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.

Time frame:
Day 1 (Baseline), Day 8, Day 15, and Final Assessment Point (Day 15 or Day 22)
Reported as:
Median · 10^9/Liter
Platelet Counts by Treatment Visit
10^9/LiterEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
Day 142.5 (36 to 49)38.0 (19 to 48)40.0 (23 to 49)
Day 850.5 (37 to 73)49.5 (27 to 88)52.0 (32 to 87)
Day 1566.0 (37 to 126)73.0 (31 to 232)81.5 (53 to 242)
Final Assessment Point66.0 (37 to 126)95.5 (35 to 232)85.5 (57 to 242)
SecondaryPlatelet Counts by Post-Treatment Visit

Platelet counts were measured by blood draw.

Time frame:
4 days post-treatment, 8 days post-treatment, and 15 days post-treatment
Reported as:
Median · 10^9/Liter
Platelet Counts by Post-Treatment Visit
10^9/LiterEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
4 days post-treatment, n=12, 13, 1163.5 (41 to 173)100.0 (38 to 271)109.0 (59 to 372)
8 days post-treatment, n=12, 13, 1267.5 (46 to 178)119.0 (40 to 387)120.0 (66 to 376)
15 days post-treatment, n=11, 13, 1165.0 (36 to 157)87.0 (29 to 382)97.0 (59 to 295)
SecondaryPlatelet Counts at Day 22

Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22.

Time frame:
Day 22
Reported as:
Median · 10^9/Liter
Platelet Counts at Day 22
10^9/LiterEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
Platelet Counts at Day 22—82.5 (35 to 126)72.5 (57 to 88)
SecondaryChange From Baseline in Platelet Counts by Treatment Visit

Platelet counts were measured by blood draw. The Final Assessment Point is the last visit during the treatment period, which is Day 15 or Day 22. Change from Baseline was calculated as the value at each visit minus the Baseline value.

Time frame:
Baseline, Day 8, Day 15, and Final Assessment Point (Day 15 or Day 22)
Reported as:
Mean · 10^9/Liter
Change From Baseline in Platelet Counts by Treatment Visit
10^9/LiterEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
Day 86.9 ± 9.4314.6 ± 11.8015.4 ± 8.96
Day 1524.8 ± 26.1354.0 ± 44.7060.0 ± 48.36
Final Assessment Point24.8 ± 26.1364.0 ± 42.5161.9 ± 47.77
SecondaryChange From Baseline in Platelet Counts by Post-Treatment Visit

Platelet counts were measured by blood draw. Change from Baseline was calculated as the value at each visit minus the Baseline value.

Time frame:
4 days post-treatment, 8 days post-treatment, and 15 days post-treatment
Reported as:
Mean · 10^9/Liter
Change From Baseline in Platelet Counts by Post-Treatment Visit
10^9/LiterEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
4 days post-treatment, n=12, 13, 1133.0 ± 36.3673.8 ± 50.1497.6 ± 83.38
8 days post-treatment, n=12, 13, 1241.5 ± 40.50100.9 ± 81.96108.3 ± 81.26
15 days post-treatment, n=11, 13, 1135.7 ± 36.5882.2 ± 83.1383.0 ± 68.31
SecondaryPercentage of Responders on Day 15

A responder was defined as a participant with a platelet count within the target range (\>=80 x 10\^9/Liter) on Day 15.

Time frame:
Day 15
Reported as:
Mean · percentage of responders
Percentage of Responders on Day 15
percentage of respondersEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
Percentage of Responders on Day 1525.0 (5.5 to 57.2)42.9 (17.7 to 71.1)58.3 (27.7 to 84.8)
SecondaryPercentage of Responders on Day 22

A responder was defined as a participant with a platelet count within the target range (\>=80 x 10\^9/Liter) on Day 22 after receiving eltrombopag for an additional week from Day 15, on which his or her platelet count was \<80 x 10\^9/Liter.

Time frame:
Day 22
Reported as:
Mean · percentage of responders
Percentage of Responders on Day 22
percentage of respondersEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
Percentage of Responders on Day 22—50.0 (11.8 to 88.2)50.0 (1.3 to 98.7)
SecondaryChange From Baseline in Platelet Counts on Day 15 by Child-Pugh Class

Change from Baseline was calculated as the Day 15 value minus the Baseline value. The Child-Pugh (CP) score (ranging from 5 to 15, with 5 being mild and 15 being severe), calculated based on total bilirubin, serum albumin, international normalized ratio, ascites, and hepatic encephalopathy, is used to assess the severity of liver disease. A CP score of 5 or 6 is classified as Class A (mild), a score of 7-9 is classified as Class B (moderate), and a score \>=10 is classified as Class C (severe). Participants with a CP score \<10 were enrolled in the study.

Time frame:
Baseline, Day 15
Reported as:
Mean · 10^9/Liter
Change From Baseline in Platelet Counts on Day 15 by Child-Pugh Class
10^9/LiterEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
Child-Pugh Class A, n=8, 8, 724.4 ± 32.5144.5 ± 27.0266.6 ± 60.59
Child-Pugh Class B, n=4, 6, 525.8 ± 5.9766.7 ± 61.9350.8 ± 27.23
SecondaryChange From Baseline in Platelet Counts on Day 15 by Sex

Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of females and males in each treatment group are illustrated by the "n's" in the category titles.

Time frame:
Baseline, Day 15
Reported as:
Mean · 10^9/Liter
Change From Baseline in Platelet Counts on Day 15 by Sex
10^9/LiterEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
Female, n=4, 4, 447.3 ± 31.1683.5 ± 69.6798.8 ± 65.18
Male, n=8, 10, 813.6 ± 15.0342.2 ± 26.9640.6 ± 23.81
SecondaryChange From Baseline in Platelet Counts on Day 15 by Age

Change from Baseline was calculated as the Day 15 value minus the Baseline value. The numbers of participants in each age category are illustrated by the "n's" in the category titles.

Time frame:
Baseline, Day 15
Reported as:
Mean · 10^9/Liter
Change From Baseline in Platelet Counts on Day 15 by Age
10^9/LiterEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
<65 years of age, n=7, 11, 519.7 ± 23.3440.2 ± 24.5049.8 ± 30.36
>=65 years of age, n=5, 3, 732.0 ± 30.82104.7 ± 71.3267.3 ± 59.36
SecondaryLog-transformed Cmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg

Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Cmax=maximum drug concentration.

Time frame:
Day 14, Day 15
Reported as:
Geometric mean · nanograms/milliliter (ng/ml)
Log-transformed Cmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg
nanograms/milliliter (ng/ml)Eltrombopag 12.5 mg
Log-transformed Cmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg3412.999 (2549.0060 to 4569.8448)
SecondaryLog-transformed Tmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg

Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. Tmax=maximum drug concentration time.

Time frame:
Day 14, Day 15
Reported as:
Geometric mean · hours
Log-transformed Tmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg
hoursEltrombopag 12.5 mg
Log-transformed Tmax on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg3.444 (2.4593 to 4.8226)
SecondaryLog-transformed AUC(0-t) and AUC(0-24) on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg

Serial PK samples were collected over a 24-hour (h) period on Days 14 and 15 in participants receiving eltrombopag 12.5 mg. A total of 8 blood samples (3 milliliters per sample) were collected at pre-dose, and at 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h post-dose. AUC(0-t)=area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration, and AUC(0-24)=area under the concentration-time curve from 0 (pre-dose) to 24 hours.

Time frame:
Day 14, Day 15
Reported as:
Geometric mean · hours * ng/ml
Log-transformed AUC(0-t) and AUC(0-24) on Days 14 and 15 in Participants Receiving Eltrombopag 12.5 mg
hours * ng/mlEltrombopag 12.5 mg
AUC(0-t)65244.180 (46617.4188 to 91313.5730)
AUC(0-24)65235.699 (46748.123 to 91034.594)

Adverse events

Collected over The time period of detecting adverse events (AEs) and serious adverse events (SAEs) was from the start of eltrombopag (Day 1) treatment to 15 days post-treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag 12.5 mg—0/12 (0%)6/12 (50%)
Eltrombopag 25 mg—0/14 (0%)7/14 (50%)
Eltrombopag 37.5 mg—1/12 (8.3%)9/12 (75%)
Most frequent serious events
Most frequent serious events
EventEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
AscitesGastrointestinal disorders0/120/141/12
Most frequent other events
Showing 10 of 55
Most frequent other events
EventEltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mg
Back painMusculoskeletal and connective tissue disorders1/120/144/12
Postoperative feverInjury, poisoning and procedural complications3/120/142/12
PyrexiaGeneral disorders0/123/142/12
Abdominal distensionGastrointestinal disorders1/120/142/12
Procedural painInjury, poisoning and procedural complications2/120/141/12
Alanine aminotransferase increasedInvestigations2/121/140/12
Aspartate aminotransferase increasedInvestigations2/121/140/12
Pleural effusionRespiratory, thoracic and mediastinal disorders2/120/142/12
AscitesGastrointestinal disorders1/120/141/12
DiarrhoeaGastrointestinal disorders1/121/141/12

Baseline characteristics

Age, Continuous
Age, Continuous(years)Eltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mgTotal
Mean62.2 ± 10.5157.7 ± 8.6966.3 ± 8.8461.8 ± 9.78
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mgTotal
Female44412
Male810826
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Eltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mgTotal
Asian-Japanese Heritage12141238
Number of participants categorized into the indicated Child-Pugh (CP) Class
Number of participants categorized into the indicated Child-Pugh (CP) Class(participants)Eltrombopag 12.5 mgEltrombopag 25 mgEltrombopag 37.5 mgTotal
Class A88723
Class B46515
Class C0000
08

Study locations

10 sites
  • GSK Investigational Site
    Fukuoka, 810-8563, Japan
  • GSK Investigational Site
    Fukuoka, 814-0180, Japan
  • GSK Investigational Site
    Fukuoka, 815-8555, Japan
  • GSK Investigational Site
    Fukuoka, 830-0011, Japan
  • GSK Investigational Site
    Fukuoka, 839-0863, Japan
  • GSK Investigational Site
    Kagoshima, 890-8520, Japan
  • GSK Investigational Site
    Kumamoto, 860-8556, Japan
  • GSK Investigational Site
    Kumamoto, 862-8655, Japan
  • GSK Investigational Site
    Nagasaki, 856-8562, Japan
  • GSK Investigational Site
    Oita, 879-5593, Japan
09

References and documents

Publications

  • Kawaguchi T, Komori A, Seike M, Fujiyama S, Watanabe H, Tanaka M, Sakisaka S, Nakamuta M, Sasaki Y, Oketani M, Hattori T, Katsura K, Sata M. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study. J Gastroenterol. 2012 Dec;47(12):1342-51. doi: 10.1007/s00535-012-0600-5. Epub 2012 Jun 8. PubMed 22674141 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2009
First posted
Mar 13, 2009
Start
Jan 2009
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Sep 23, 2010
Last update
May 12, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00861601
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 13, 2009
Start date
Jan 2009
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Sep 23, 2010
Last update
May 12, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion